ArticleCirculation2020
Building the Foundation for a New Era of Quadruple Therapy in Heart Failure.
Article in Circulation, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 18 citations in OpenAlex.
- Coronary perfusion pressure is associated with adverse outcomes in advanced heart failure.Perfusion · 2023Trial
- Implementing community-based heart failure screening in primary care settings: a population-based pilot study in Shanghai, China.BMC primary care · 2025Observational
- Initiation of vericiguat and short-term cardiovascular function improvement in heart failure patients with and without worsened renal function.Frontiers in cardiovascular medicine · 2025Article
- Role of macrophage polarization in heart failure and traditional Chinese medicine treatment.Frontiers in pharmacology · 2024Review
- Initial Experience of Vericiguat Treatment in Patients with Heart Failure and Reduced Ejection Fraction.Journal of clinical medicine · 2023Article
- Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction.European heart journal · 2022Article
- Vericiguat for Heart Failure with Reduced Ejection Fraction.Current cardiology reports · 2021Review
- Sodium-glucose Co-transporter 2 Inhibitors: a New Path for Heart Failure Treatment.Korean circulation journal · 2021Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.